Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VYNE 
Vyne Therapeutics Inc (VYNE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: VYNE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.03% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.64M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 4 | Beta 1.91 | 52 Weeks Range 0.28 - 4.30 | Updated Date 10/16/2025 |
52 Weeks Range 0.28 - 4.30 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -10930.43% |
Management Effectiveness
Return on Assets (TTM) -40.54% | Return on Equity (TTM) -67.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -31391944 | Price to Sales(TTM) 20.26 |
Enterprise Value -31391944 | Price to Sales(TTM) 20.26 | ||
Enterprise Value to Revenue 10.04 | Enterprise Value to EBITDA 1.84 | Shares Outstanding 25472165 | Shares Floating 23251756 |
Shares Outstanding 25472165 | Shares Floating 23251756 | ||
Percent Insiders 5.31 | Percent Institutions 34.53 |
Upturn AI SWOT
Vyne Therapeutics Inc
Company Overview
History and Background
Vyne Therapeutics Inc., formerly Menlo Therapeutics Inc., focuses on developing and commercializing therapeutics for dermatology. The company experienced a significant restructuring and strategic shift, including name changes and changes in core business areas.
Core Business Areas
- Dermatology: Vyne Therapeutics' primary focus is on developing and commercializing treatments for dermatological conditions. This includes exploring new therapies and formulations.
Leadership and Structure
Details regarding Vyne Therapeutics' current leadership team and organizational structure are generally available on their investor relations page and company profile.
Top Products and Market Share
Key Offerings
- AMZEEQ: AMZEEQ (minocycline) is a topical treatment for inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. Revenue is not available. Competitors include generic minocycline products, as well as other topical acne treatments.
- ZILXI: ZILXI (minocycline) topical foam is a topical treatment for inflammatory lesions of rosacea in adults. Revenue is not available. Competitors include other topical rosacea treatments like metronidazole and azelaic acid products.
Market Dynamics
Industry Overview
The dermatology market is characterized by increasing demand for effective treatments for skin conditions, driven by factors such as an aging population, rising awareness of skin health, and the availability of advanced treatments.
Positioning
Vyne Therapeutics is a player in the dermatology market, with a focus on topical minocycline formulations for acne and rosacea. Its competitive advantage, if any, lies in the specific formulations and delivery systems of its products.
Total Addressable Market (TAM)
The global dermatology market is estimated to be in the tens of billions of dollars annually. Vyne Therapeutics' positioning within this TAM is dependent on the market penetration of AMZEEQ and ZILXI.
Upturn SWOT Analysis
Strengths
- Proprietary topical minocycline formulations (AMZEEQ and ZILXI)
- Focus on specific dermatological conditions
- Experienced management team
Weaknesses
- Limited product portfolio
- High dependence on the success of AMZEEQ and ZILXI
- Relatively small market capitalization
Opportunities
- Expanding indications for existing products
- Developing new dermatology products
- Strategic partnerships and collaborations
Threats
- Competition from generic and branded dermatology products
- Regulatory challenges and changes
- Pricing pressures
Competitors and Market Share
Key Competitors
- MNK
- BHC
- DERM
Competitive Landscape
Vyne Therapeutics faces stiff competition from larger, more established pharmaceutical companies. Its success depends on effectively marketing its products and expanding its product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Analyzing Vyne Therapeutics' growth trends over the past years necessitates access to detailed financial statements.
Future Projections: Projections for Vyne Therapeutics' future growth based on analyst estimates require real-time market research data.
Recent Initiatives: Recent strategic initiatives undertaken by Vyne Therapeutics are generally communicated through press releases and investor relations updates.
Summary
Vyne Therapeutics is a dermatology-focused company with a limited product portfolio, relying heavily on the success of AMZEEQ and ZILXI. While it has potential for growth through expanding indications and strategic partnerships, it faces significant competition from larger pharmaceutical companies and pricing pressures. The lack of dividends and smaller market cap is of concern. It will need to grow revenue significantly to be a stronger player.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Financial news sources
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vyne Therapeutics Inc
Exchange NASDAQ | Headquaters Bridgewater, NJ, United States | ||
IPO Launch date 2018-01-25 | CEO, President & Director Mr. David T. Domzalski | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://vynetherapeutics.com |
Full time employees 13 | Website https://vynetherapeutics.com | ||
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.